You are here: Industry Insights > Biogen

News List

Alzheimer’s Disease - Recent Advances in Treatment Neeta Ratanghayra
August 06, 2021
Alzheimer's disease (AD) is a neurodegenerative disease affecting millions of people globally.
Chinese BTK Inhibitor Orelabrutinib Gone Global, What Other Drugs Have Been Ok'd Overseas in 2021 PharmaSources/Dopine
July 26, 2021
On July 13, InnoCare Pharma and Biogen made joint announcement that they have entered into an agreement on the license and cooperation of the BTK inhibitor Orelabrutinib.
Biogen urges Medicare to reverse proposed limits on coverage of Alzheimer's drug FirstWordPharma
February 11, 2022
Biogen is urging Medicare to broadly reimburse its Alzheimer's drug Aduhelnm, in response to a proposal by the US Centers for Medicaid and Medicare Services (CMS) to sharply limit coverage of new drugs for the disease...
Samsung Biologics to buy out Biogen's stake in Samsung Bioepis CPhIonline
January 29, 2022
Samsung Biologics has reached an agreement for the buyout of Biogen’s stake in the Samsung Bioepis joint venture for USD $2.3 billion.
Samsung Biologics to acquire Biogen’s stake in Samsung Bioepis for $2.3bn Pharmaceutical-Technology
January 29, 2022
Biogen is eligible to receive up to $50m from Samsung Biologics on meeting some commercial milestones.
Samsung Biologics Acquires Full Ownership of Samsung Bioepis contractpharma
January 29, 2022
Buys out Biogen’s stake in the joint venture for $2.3 billion.
Biogen to obtain licence for Ionis’ investigational SMA therapy Pharmaceutical-Technology
January 06, 2022
Biogen will handle the expenses associated with the development, production and potential marketing of BIIB115.
Biogen Exercises Option for Exclusive License to BIIB115 contractpharma
January 04, 2022
BIIB115 is an investigational antisense oligonucleotide (ASO) in development for spinal muscular atrophy.
Biogen announces results from Phase IIIb NOVA study for MS europeanpharmaceuticalreview
August 06, 2021
Results from the NOVA study show every six-week dosing with natalizumab is as effective as every four-week in relapsing-remitting MS.
Alzheimer’s treatment lowers tau by nearly 50 percent in Phase I trials europeanpharmaceuticalreview
July 30, 2021
Biogen and Ionis announced positive topline data on investigational Alzheimer’s treatment, indicating 50 percent tau protein reduction.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page